Results 11 to 20 of about 628,481 (260)
Immunogenicity and humanization of single‐domain antibodies [PDF]
The FEBS Journal, 2021 Single‐domain antibodies (sdAbs), the autonomous variable domains of camelid and shark heavy‐chain antibodies, have many desirable properties as components of biologic drugs. However, their sequences may increase the risk of immunogenicity and antidrug antibody (ADA) development in humans, and thus, sdAbs are routinely humanized during development ...
Rossotti, Martin A. +3 more
openaire +2 more sources
Single-domain antibodies make a difference [PDF]
Science, 2021 A double hit with one antibody construct may avoid viral ...
Xavier, Saelens, Bert, Schepens
openaire +2 more sources
Single‐Domain Antibodies and Their Utility
Current Protocols in Immunology, 2013 AbstractEngineered monoclonal antibody fragments have gained market attention due to their versatility and tailor‐made potential and are now considered to be an important part of future immunobiotherapeutics. Single‐domain antibodies (sdAbs), also known as nanobodies, are derived from VHHs [variable domains (V) of heavy‐chain‐only antibodies (HCAb)] of
Baral, Toya Nath +2 more
openaire +4 more sources
Bglbrick strategy for the construction of single domain antibody fusions
Heliyon, 2017 Single domain antibodies, recombinantly expressed variable domains derived from camelid heavy chain antibodies, are often expressed as multimers for detection and therapeutic applications.
Ellen R. Goldman +3 more
doaj +1 more source
Molecular Therapy: Nucleic Acids, 2020 To date, mRNA-based biologics have mainly been developed for prophylactic and therapeutic vaccination to combat infectious diseases or cancer. In the past years, optimization of the characteristics of in vitro transcribed mRNA has led to significant ...
Lien Van Hoecke +10 more
doaj +1 more source
A single domain antibody-based Luminex assay for the detection of SARS-CoV-2 in clinical samples [PDF]
Frontiers in ImmunologyHua-Wei Chen +2 more
exaly +2 more sources
NbX: Machine Learning-Guided Re-Ranking of Nanobody–Antigen Binding Poses
Pharmaceuticals, 2021 Modeling the binding pose of an antibody is a prerequisite to structure-based affinity maturation and design. Without knowing a reliable binding pose, the subsequent structural simulation is largely futile.
Chunlai Tam +2 more
doaj +1 more source
Conjugation of biotin-coated luminescent quantum dots with single domain antibody-rhizavidin fusions
Biotechnology Reports, 2016 Straightforward and effective methods are required for the bioconjugation of proteins to surfaces and particles. Previously we demonstrated that the fusion of a single domain antibody with the biotin binding molecule rhizavidin provided a facile method ...
Jinny L. Liu +9 more
doaj +1 more source
A comparison of the binding sites of antibodies and single-domain antibodies
Frontiers in Immunology, 2023 Antibodies are the largest class of biotherapeutics. However, in recent years, single-domain antibodies have gained traction due to their smaller size and comparable binding affinity. Antibodies (Abs) and single-domain antibodies (sdAbs) differ in the structures of their binding sites: most significantly, single-domain antibodies lack a light chain and
Gemma L. Gordon +5 more
openaire +3 more sources
Single domain antibody: Development and application in biotechnology and biopharma. [PDF]
Immunol RevSummaryHeavy‐chain antibodies (HCAbs) are a unique type of antibodies devoid of light chains, and comprised of two heavy chains‐only that recognize their cognate antigen by virtue of a single variable domain also referred to as VHH, single domain antibody (sdAb), or nanobody (Nb). These functional HCAbs, serendipitous discovered about three decades ago,
Yu T +4 more
europepmc +4 more sources